
Last updated: 2026-09-05 16:19:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Larimar Therapeutics, Inc. (LRMR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.83, with a market capitalization of $402.03M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.72 to $6.42. This page covers its latest market performance, valuation, price trends and company information.
$402.03M | |
$3.82 | |
$25.87 | |
$1.53 | |
$3.83 | |
339.29K | |
-- | |
-- | |
$6.42 | |
$2.72 | |
-- | |
-- |
Larimar Therapeutics, Inc. (LRMR) last closed at $3.83 as of 2026-09-04 23:31:00, unchanged from the previous close of $3.83.
During the latest regular trading session, LRMR traded between $1.53 and $25.87, with a volume of 339.29K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Larimar Therapeutics, Inc. (LRMR) moved from $3.98 to $3.83, representing a decline of 3.89% ($0.15).
The stock traded between $3.80 and $3.99 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 675.47 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 30.0%
LRMR is currently trading at $3.83, placing it 30.0% of the way from its 52-week low of $2.72 to its 52-week high of $6.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 71 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Larimar Therapeutics, Inc. (LRMR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.